Professor Oriana Ciani
- Affiliate (School of Health & Wellbeing)
email:
Oriana.Ciani@glasgow.ac.uk
MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Berkeley Square, 99 Berkeley Street, G3 7HR
Publications
2024
Wallach, J. D., Yoon, S., Doernberg, H., Glick, L. R., Ciani, O., Taylor, R. S. , Mooghali, M., Ramachandran, R. and Ross, J. S. (2024) Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments. JAMA: Journal of the American Medical Association, (doi: 10.1001/jama.2024.4175) (PMID:38648042) (Early Online Publication)
2023
Ciani, O. et al. (2023) A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials. EClinicalMedicine, 65, 102283. (doi: 10.1016/j.eclinm.2023.102283) (PMID:37877001) (PMCID:PMC10590868)
Manyara, A. M. et al. (2023) Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate endpoints in trials: a scoping review. Journal of Clinical Epidemiology, 160, pp. 83-99. (doi: 10.1016/j.jclinepi.2023.06.013) (PMID:37380118)
2022
Ciani, O., Manyara, A. M. , Chen, A.-W. and Taylor, R. S. (2022) Surrogate endpoints in trials: a call for better reporting. Trials, 23, 991. (doi: 10.1186/s13063-022-06904-7) (PMID:36503559) (PMCID:PMC9743760)
Ciani, O., Manyara, A. M. and Taylor, R. S. (2022) Surrogate endpoints in cardio-thoracic trials: a call for better reporting and improved interpretation of trial findings. European Journal of Cardio-Thoracic Surgery, 62(4), ezac449. (doi: 10.1093/ejcts/ezac449) (PMID:36112148)
Manyara, A. , Davies, P., Stewart, D., Wells, V. , Weir, C., Young, A., Taylor, R. and Ciani, O. (2022) Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol. BMJ Open, 12(10), e062798. (doi: 10.1136/bmjopen-2022-062798) (PMID:36229145) (PMCID:PMC9562307)
Manyara, A. M. et al. (2022) Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE. BMJ Open, 12(10), e064304. (doi: 10.1136/bmjopen-2022-064304) (PMID:36220321) (PMCID:PMC9557267)
Ciani, O., Grigore, B. and Taylor, R. S. (2022) Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence. Health Economics, 31(S1), pp. 44-72. (doi: 10.1002/hec.4524) (PMID:35608044) (PMCID:PMC9546394)
Ciani, O., Manyara, A. M. and Taylor, R. S. (2022) Need for better reporting of trials with surrogate endpoints – SPIRIT|CONSORT-SURROGATE extensions. Journal of Epidemiology and Community Health, 76(9), pp. 769-770. (doi: 10.1136/jech-2022-219294) (PMID:35750481) (PMCID:PMC9380472)
Ciani, O., Manyara, A. M. and Taylor, R. S. (2022) Surrogate endpoints in trials – a call for better reporting. British Medical Journal, 378, o1912. (doi: 10.1136/bmj.o1912) (PMID:35905986)
Manyara, A. M. , Ciani, O. and Taylor, R. S. (2022) A call for better reporting of trials using surrogate primary endpoints. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 8(1), e12340. (doi: 10.1002/trc2.12340) (PMID:35910671) (PMCID:PMC9323346)
Manyara, A. M. , Ciani, O. and Taylor, R. S. (2022) Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers. Alzheimer's and Dementia, 8(1), e12344. (doi: 10.1002/trc2.12344) (PMID:35910664) (PMCID:PMC9323349)
Articles
Wallach, J. D., Yoon, S., Doernberg, H., Glick, L. R., Ciani, O., Taylor, R. S. , Mooghali, M., Ramachandran, R. and Ross, J. S. (2024) Associations between surrogate markers and clinical outcomes for nononcologic chronic disease treatments. JAMA: Journal of the American Medical Association, (doi: 10.1001/jama.2024.4175) (PMID:38648042) (Early Online Publication)
Ciani, O. et al. (2023) A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials. EClinicalMedicine, 65, 102283. (doi: 10.1016/j.eclinm.2023.102283) (PMID:37877001) (PMCID:PMC10590868)
Manyara, A. M. et al. (2023) Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate endpoints in trials: a scoping review. Journal of Clinical Epidemiology, 160, pp. 83-99. (doi: 10.1016/j.jclinepi.2023.06.013) (PMID:37380118)
Ciani, O., Manyara, A. M. , Chen, A.-W. and Taylor, R. S. (2022) Surrogate endpoints in trials: a call for better reporting. Trials, 23, 991. (doi: 10.1186/s13063-022-06904-7) (PMID:36503559) (PMCID:PMC9743760)
Ciani, O., Manyara, A. M. and Taylor, R. S. (2022) Surrogate endpoints in cardio-thoracic trials: a call for better reporting and improved interpretation of trial findings. European Journal of Cardio-Thoracic Surgery, 62(4), ezac449. (doi: 10.1093/ejcts/ezac449) (PMID:36112148)
Manyara, A. , Davies, P., Stewart, D., Wells, V. , Weir, C., Young, A., Taylor, R. and Ciani, O. (2022) Scoping and targeted reviews to support development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: protocol. BMJ Open, 12(10), e062798. (doi: 10.1136/bmjopen-2022-062798) (PMID:36229145) (PMCID:PMC9562307)
Manyara, A. M. et al. (2022) Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE. BMJ Open, 12(10), e064304. (doi: 10.1136/bmjopen-2022-064304) (PMID:36220321) (PMCID:PMC9557267)
Ciani, O., Grigore, B. and Taylor, R. S. (2022) Development of a framework and decision tool for the evaluation of health technologies based on surrogate endpoint evidence. Health Economics, 31(S1), pp. 44-72. (doi: 10.1002/hec.4524) (PMID:35608044) (PMCID:PMC9546394)
Ciani, O., Manyara, A. M. and Taylor, R. S. (2022) Need for better reporting of trials with surrogate endpoints – SPIRIT|CONSORT-SURROGATE extensions. Journal of Epidemiology and Community Health, 76(9), pp. 769-770. (doi: 10.1136/jech-2022-219294) (PMID:35750481) (PMCID:PMC9380472)
Ciani, O., Manyara, A. M. and Taylor, R. S. (2022) Surrogate endpoints in trials – a call for better reporting. British Medical Journal, 378, o1912. (doi: 10.1136/bmj.o1912) (PMID:35905986)
Manyara, A. M. , Ciani, O. and Taylor, R. S. (2022) A call for better reporting of trials using surrogate primary endpoints. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 8(1), e12340. (doi: 10.1002/trc2.12340) (PMID:35910671) (PMCID:PMC9323346)
Manyara, A. M. , Ciani, O. and Taylor, R. S. (2022) Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers. Alzheimer's and Dementia, 8(1), e12344. (doi: 10.1002/trc2.12344) (PMID:35910664) (PMCID:PMC9323349)